FAQ: Pelage Pharmaceuticals' $120 Million Funding and Regenerative Hair Growth Therapy
Summary
Pelage Pharmaceuticals has raised $120 million in Series B financing to advance PP405, its regenerative hair growth therapy that reactivates dormant hair follicle stem cells. This funding will accelerate clinical development of a potential first-in-class solution for hair loss in both men and women.
What is Pelage Pharmaceuticals and what have they accomplished?
Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotechnology company based in Los Angeles that has raised $120 million in Series B financing to accelerate development of its flagship hair restoration therapy.
What is PP405 and how does it work?
PP405 is Pelage’s lead program - a topical small molecule designed to reactivate dormant hair follicle stem cells, potentially offering a first-in-class solution for hair loss by stimulating the body’s own regenerative machinery.
Who led the funding round and who participated?
The $120 million Series B round was co-led by ARCH Venture Partners and GV (formerly Google Ventures), with participation from existing backers Main Street Advisors, Visionary Ventures, and YK Bioventures.
What is the current status of PP405’s development?
PP405 is currently in Phase 2a clinical trials, representing a novel, non-invasive approach to restoring natural hair growth by targeting the body’s regenerative potential.
Who is leading Pelage Pharmaceuticals and what is their background?
Pelage is led by CEO Daniel Gil, Ph.D., a veteran scientist and biotech leader who previously held senior scientific roles at Amgen and Regeneron Pharmaceuticals, where he led discovery programs in stem cell signaling and tissue regeneration.
How does Pelage’s approach differ from other hair restoration companies?
Unlike competitors focusing on cell therapy or transplant-based interventions, Pelage’s small-molecule approach stimulates the body’s own regenerative machinery, which could simplify treatment delivery and broaden patient access.
What changes occurred in Pelage’s leadership as part of this funding?
Cathy Friedman, Executive Venture Partner at GV who led Pelage’s Series A round, has been appointed Chair of the Board, and Richard Heyman, Ph.D., Venture Partner at ARCH Venture Partners, will also join the board.
What is the potential market size for hair restoration treatments?
The hair restoration market is projected to exceed $10 billion globally by 2030, according to industry analysts cited in the content.
What are the broader implications of Pelage’s technology beyond hair restoration?
Pelage’s long-term ambition is to ‘redefine regenerative medicine through stem cell activation,’ positioning the company not only in dermatology but also across broader tissue-repair applications.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at citybiz
Article Control ID: 255012